[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment...
Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes The...
Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD) The FDA has approved updates to...
FDA approves Roche’s Vabysmo prefilled syringe (PFS) for three leading causes of vision loss Vabysmo PFS is the first and only syringe prefilled...
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell...
Roche’s Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO) Positive recommendation is based on two Phase III...
CHMP recommends EU approval of Roche’s PiaSky for people with PNH, a rare, life-threatening blood condition If approved, PiaSky will be the first...
Roche expands access to cervical cancer screening tools with two new WHO prequalification designations, including HPV self-collection The World...
Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary...
Roche launches new analytical units for cobas® pro integrated solutions delivering greater efficiency and capacity to laboratories The cobas® c...
Roche launches new highly-sensitive test to more easily diagnose patients who may have B-cell lymphoma The VENTANA Kappa and Lambda Dual ISH mRNA...
Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell...
Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization The test uses highly...
European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung...
Five-year data for Roche’s Evrysdi show the majority of treated children with a severe form of spinal muscular atrophy (SMA) achieved or...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.